DK3494134T3 - Manipulerede polypeptider og deres anvendelse - Google Patents

Manipulerede polypeptider og deres anvendelse

Info

Publication number
DK3494134T3
DK3494134T3 DK17754535.7T DK17754535T DK3494134T3 DK 3494134 T3 DK3494134 T3 DK 3494134T3 DK 17754535 T DK17754535 T DK 17754535T DK 3494134 T3 DK3494134 T3 DK 3494134T3
Authority
DK
Denmark
Prior art keywords
engineered polypeptides
engineered
polypeptides
Prior art date
Application number
DK17754535.7T
Other languages
English (en)
Inventor
Karthik Viswanathan
Boopathy Ramakrishnan
Kristin Narayan
Andrew M Wollacott
Brian Booth
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Application granted granted Critical
Publication of DK3494134T3 publication Critical patent/DK3494134T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
DK17754535.7T 2016-08-02 2017-08-02 Manipulerede polypeptider og deres anvendelse DK3494134T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370201P 2016-08-02 2016-08-02
US201762485671P 2017-04-14 2017-04-14
PCT/US2017/045126 WO2018052556A1 (en) 2016-08-02 2017-08-02 Engineered polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
DK3494134T3 true DK3494134T3 (da) 2026-02-09

Family

ID=59656189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17754535.7T DK3494134T3 (da) 2016-08-02 2017-08-02 Manipulerede polypeptider og deres anvendelse

Country Status (22)

Country Link
US (3) US11858980B2 (da)
EP (1) EP3494134B1 (da)
JP (2) JP7464389B2 (da)
KR (2) KR102777127B1 (da)
CN (3) CN118085091A (da)
AU (2) AU2017325654B2 (da)
BR (1) BR112019001989A2 (da)
CA (1) CA3032820A1 (da)
CL (3) CL2019000261A1 (da)
CO (1) CO2019000931A2 (da)
DK (1) DK3494134T3 (da)
ES (1) ES3062797T3 (da)
FI (1) FI3494134T3 (da)
HR (1) HRP20260151T1 (da)
IL (2) IL264590B2 (da)
LT (1) LT3494134T (da)
MX (1) MX2019001458A (da)
NZ (1) NZ750257A (da)
PT (1) PT3494134T (da)
SG (1) SG11201900616UA (da)
SI (1) SI3494134T1 (da)
WO (1) WO2018052556A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM
FI3494134T3 (fi) 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
MA45919A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
JP7009448B2 (ja) * 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
WO2019099374A2 (en) * 2017-11-14 2019-05-23 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
CA3089602A1 (en) * 2018-01-26 2019-08-01 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life
KR20210043483A (ko) * 2018-03-05 2021-04-21 온코이뮨, 아이앤씨. 후천성 면역 결핍 증후군(hiv/aids)을 치료하기 위한 가용성 cd24의 사용 방법
JP2021520352A (ja) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス， インコーポレイテッド 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法
EP3805400A4 (en) * 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
WO2020106220A1 (en) * 2018-11-22 2020-05-28 Agency For Science, Technology And Research Modified fc region
CN113544152B (zh) 2018-12-18 2024-10-15 勃林格殷格翰国际加拿大公司 Flt3激动剂抗体及其用途
CN113227131B (zh) * 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
BR112021023483A2 (pt) 2019-05-23 2022-02-08 Univ Xiamen Novo anticorpo anti-vírus da hepatite b e seus usos
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN114423782A (zh) * 2019-09-04 2022-04-29 西达赛奈医疗中心 不含钙调磷酸酶抑制剂的ctla4-ig+抗il6/il6r用于对实体器官移植受体进行长期免疫抑制的用途
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
WO2021119467A1 (en) 2019-12-11 2021-06-17 Visterra, Inc. Compositions and methods for treating and preventing influenza
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN111254207A (zh) * 2020-01-22 2020-06-09 郑州大学第一附属医院 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用
CA3187823A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
CN120309734A (zh) 2021-01-13 2025-07-15 威特拉公司 人源化补体5a受体1抗体和其使用方法
AU2022211021A1 (en) 2021-01-20 2023-08-03 Visterra, Inc. Interleukin-2 mutants and uses thereof
CN117202938A (zh) * 2021-02-25 2023-12-08 奇达拉治疗公司 变体Fc结构域及其用途
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN120131911A (zh) 2021-12-01 2025-06-13 威特拉公司 使用白细胞介素-2药剂的方法
MX2024009868A (es) 2022-02-11 2024-08-20 Visterra Inc Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
CN115028738B (zh) * 2022-06-14 2025-05-16 天津医科大学 一种Fc融合蛋白双重靶向降解剂及应用
WO2024027793A1 (en) * 2022-08-05 2024-02-08 I-Mab Biopharma (Hangzhou) Co., Ltd. Bispecific antibodies targeting ifnar1 and blys
EP4606819A1 (en) * 2022-10-18 2025-08-27 Crosspoint Therapeutics Inc. Human antibody fc domain variant and use thereof
WO2024097938A1 (en) * 2022-11-04 2024-05-10 Cephalon, LLC Compositions and methods for increasing transport into the brain
GEAP202616844A (en) * 2023-03-06 2026-01-12 Biocad Joint Stock Co Antibody-like molecule comprising heterodimer of human cd1b (cluster of differentiation 1) protein
WO2024211779A1 (en) * 2023-04-05 2024-10-10 The Regents Of The University Of California Affinity peptides for diagnosis and treatment of viral infections
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
US20260028384A1 (en) 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
WO2026090160A2 (en) 2024-10-22 2026-04-30 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1572091A4 (en) 2002-07-09 2008-03-05 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
AU2012203476A1 (en) * 2003-11-12 2012-07-05 Biogen Idec Ma Inc. Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
KR101834999B1 (ko) 2008-10-14 2018-03-06 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
US8775090B2 (en) * 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
AU2015200990B2 (en) 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9013699B2 (en) 2009-11-09 2015-04-21 Cantwell G. Carson Vaccine testing system
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2012032080A1 (en) * 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
AU2012214643B2 (en) 2011-02-07 2016-12-15 Research Development Foundation Engineered immunoglobulin Fc polypeptides
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
KR102168731B1 (ko) 2011-03-30 2020-10-23 추가이 세이야쿠 가부시키가이샤 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013047752A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
BR112014007484A2 (pt) 2011-09-30 2017-04-04 Chugai Pharmaceutical Co Ltd molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013096221A1 (en) 2011-12-21 2013-06-27 Amgen Inc. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
HK1211037A1 (en) 2012-02-11 2016-05-13 霍夫曼-拉罗奇有限公司 R-spondin translocations and methods using the same
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
JP6280300B2 (ja) 2012-08-24 2018-02-14 中外製薬株式会社 脳疾患治療剤
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
FR3024453B1 (fr) 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
EP3215528B1 (en) * 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
HK1249532A1 (zh) 2015-04-07 2018-11-02 F. Hoffmann-La Roche Ag 具有激动剂活性的抗原结合复合体及使用方法
FR3035879B1 (fr) 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
MA43773B1 (fr) 2016-03-14 2026-01-30 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
FI3494134T3 (fi) 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
EP4424707A3 (en) 2017-09-19 2024-11-13 Tillotts Pharma AG Antibody variants

Also Published As

Publication number Publication date
RU2019104889A3 (da) 2020-09-04
IL315729A (en) 2024-11-01
FI3494134T3 (fi) 2026-02-19
IL264590A (en) 2019-02-28
AU2017325654B2 (en) 2024-09-05
ES3062797T3 (en) 2026-04-14
SG11201900616UA (en) 2019-02-27
RU2019104889A (ru) 2020-09-04
LT3494134T (lt) 2026-02-25
KR20190038607A (ko) 2019-04-08
CO2019000931A2 (es) 2019-02-08
JP2019531705A (ja) 2019-11-07
IL264590B1 (en) 2025-12-01
KR20250036943A (ko) 2025-03-14
WO2018052556A8 (en) 2019-03-14
BR112019001989A2 (pt) 2019-08-20
CA3032820A1 (en) 2018-03-22
CN118085091A (zh) 2024-05-28
KR102777127B1 (ko) 2025-03-07
NZ750257A (en) 2026-02-27
AU2024270619A1 (en) 2025-01-02
MX2019001458A (es) 2019-07-04
JP2022120132A (ja) 2022-08-17
CL2022000036A1 (es) 2022-10-28
US11858980B2 (en) 2024-01-02
WO2018052556A1 (en) 2018-03-22
US20200277358A1 (en) 2020-09-03
CN118388638A (zh) 2024-07-26
HRP20260151T1 (hr) 2026-03-27
PT3494134T (pt) 2026-03-02
CL2019000261A1 (es) 2019-06-28
IL264590B2 (en) 2026-04-01
EP3494134B1 (en) 2025-12-10
US20180037634A1 (en) 2018-02-08
EP3494134A1 (en) 2019-06-12
AU2017325654A1 (en) 2019-02-14
SI3494134T1 (sl) 2026-04-30
US20250296982A1 (en) 2025-09-25
JP7464389B2 (ja) 2024-04-09
CN110072887A (zh) 2019-07-30
CL2024003234A1 (es) 2025-03-07

Similar Documents

Publication Publication Date Title
IL285286A (en) Transposase polypeptides and uses thereof
HRP20260151T1 (hr) Modificirani polipeptidi i njihova uporaba
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3988117T3 (da) Terapeutiske antistoffer og deres anvendelser
DK3559227T3 (da) Proteasevarianter og anvendelser deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3356558T3 (da) Sirs patogenbiomarkører og anvendelser deraf
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3290441T3 (da) Rgma-bindingsprotein og anvendelse deraf
DK3434737T3 (da) Modificerede pigmenter og deres anvendelse
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf